In vitro incubation of
all-trans-retinol(atROL) with
kidney homogenate from vitaminA-deficient and retinoic acid-supplemented (VAD-RAS) female ratsproduces a new retinol metabolite.Reverse-phase (RP) and normal-phase (NP) high-performance liquidchromatography (HPLC) analysisshowed that this metabolite coelutes with the un
known
all-
trans-retinol (atROL) metabolitepreviouslyfound in the day 10 conceptus and
kidneys of vitamin A-deficient ratsmaintained on
all-
trans-retinoicacid (VAD-RA) and given 2
![](/images/entities/mgr.gif)
g of [
3H]atROL.Normal-phase (NP) HPLC purification of the metabolitecollected from a RP HPLC column further separated the radiolabeledmaterial into two components. Thetwo isolated compounds have identical or very similar spectroscopicproperties. Their nuclear magneticresonance (
1H NMR) and mass spectra (MS) indicated thatthey are isomers. Spectroscopic studies ofthe metabolites and their derivatives showed that they are nine-carbonfragments resulting from an oxidativecleavage of the side chain of atROL. The cleavage occurs at C-9,and the product is then oxidized to a
keto group. The primary hydroxy group from atROL is preserved inthe metabolite. A sulfide bridge isformed between C-11 and C-14, which interrupts the conjugation.The formation of the new metabolites,possessing a 2,5-dihydrothiophene ring, is catalyzed by anenzyme(s) located in the cytosolic fraction of
kidneys. The process represents a new retinol metabolic pathway;however, its biological significance isun
known.